SBIR/STTR Research Award

A Novel Target for CAR T Cell Therapy Using Precision Oncology Approaches

Award identifier e71764a07908e49c50a1e2d4afb6044cf43d4aba81fc91dc2133b1b3129cfb44Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$293,897

Program and phase

SBIR · Phase I

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
JAVELIN ONCOLOGY INC
Proposal award date
2019-05-10
Contract end date
2020-04-30
UEI
G4KVF7DE12S4
Solicitation number
PA18-574
Topic code
102

Research abstract

Project Summary This year cancer is expected to claimmillion lives worldwideWorld Health OrganizationItrepresents the leading cause of death in the United States and its prevalence continues to groweach yearConventional treatment options tend to be limited in efficacy with highly toxic sideeffectsNewermonoclonal antibody based therapies have offered promise to for some types ofcancerparticularly blood tumorsbut these often fall short as wellTypicallythese treatments are delivered based on the location of the tumor and do not consider whether theindividual patient actually expresses the targetIn additionthe most common tumor antigens tendto have significant expression on healthy tissues as wellcreatingon targetoff tumortoxicitiesRecent advances in nucleotide sequencing technology have created a proliferation inprecision oncology capabilitiesThese new capabilities have allowed patients and their tumors tobe stratifiedknowing exactly which patientstumors express druggable targetsThese advanceshave created a gap in the field between the ability to identify unique tumor markers and theability deliver therapies based on those markersThe maturation of precision oncology establishesan urgent need for development of therapeutics to novel targets intended to treat cancers based ontheir genetic composition rather than their locationUsing proprietary computational biology techniqueswe have populated a list of antigens that arevery highly expressed on small subsetsof tumors but are not expressed or have very lowexpression on healthy tissuesWith this Phase I SBIRwe hope to advance our first therapeuticsto one of these targets through pre clinical proof of concept experiments and lead candidateselectionThese experiments will drive the selection of the optimal format of this therapeuticand will justify the IND enabling pre clinical work required to prepare these novel therapeuticsfor delivery to patients Project Narrative Despite recent advances in the diagnosis and treatment of canceroverAmericans will die from the disease this yearWe are creating new therapies toward unique targetsexpressed only on cancer cellsand establishing a critical pathway for identifying which patients have tumors expressing these targetsIf successfulthis work will provide an accelerated route for creating new cancer drugs and delivering them to the patients who need them

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

2 SBIR/STTR records share this UEI (2019–2022). Reported award amounts total $622,843. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.